🎉 M&A multiples are live!
Check it out!

Keros Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Keros Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Keros Therapeutics Overview

About Keros Therapeutics

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.


Founded

2015

HQ

United States of America
Employees

169

Website

kerostx.com

Financials

LTM Revenue $4.1M

LTM EBITDA -$204M

EV

-$24.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Keros Therapeutics Financials

Keros Therapeutics has a last 12-month revenue of $4.1M and a last 12-month EBITDA of -$204M.

In the most recent fiscal year, Keros Therapeutics achieved revenue of $3.5M and an EBITDA of -$186M.

Keros Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Keros Therapeutics valuation multiples based on analyst estimates

Keros Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.2M $3.5M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$152M -$186M XXX XXX XXX
EBITDA Margin -100779% -5234% XXX XXX XXX
Net Profit -$105M -$153M XXX XXX XXX
Net Margin -69324% -4310% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Keros Therapeutics Stock Performance

As of April 15, 2025, Keros Therapeutics's stock price is $13.

Keros Therapeutics has current market cap of $517M, and EV of -$24.3M.

See Keros Therapeutics trading valuation data

Keros Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$24.3M $517M XXX XXX XXX XXX $-4.89

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Keros Therapeutics Valuation Multiples

As of April 15, 2025, Keros Therapeutics has market cap of $517M and EV of -$24.3M.

Keros Therapeutics's trades at -6.0x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.

Analysts estimate Keros Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Keros Therapeutics and 10K+ public comps

Keros Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$24.3M XXX XXX XXX
EV/Revenue -6.8x XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -2.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Keros Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Keros Therapeutics Valuation Multiples

Keros Therapeutics's NTM/LTM revenue growth is 77%

Keros Therapeutics's revenue per employee for the last fiscal year averaged $21K, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Keros Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Keros Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Keros Therapeutics and other 10K+ public comps

Keros Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2251% XXX XXX XXX XXX
EBITDA Margin -5234% XXX XXX XXX XXX
EBITDA Growth 22% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -5158% XXX XXX XXX XXX
Revenue per Employee $21K XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1148% XXX XXX XXX XXX
R&D Expenses to Revenue 4891% XXX XXX XXX XXX
Opex to Revenue 6004% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Keros Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Keros Therapeutics M&A and Investment Activity

Keros Therapeutics acquired  XXX companies to date.

Last acquisition by Keros Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Keros Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Keros Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Keros Therapeutics

When was Keros Therapeutics founded? Keros Therapeutics was founded in 2015.
Where is Keros Therapeutics headquartered? Keros Therapeutics is headquartered in United States of America.
How many employees does Keros Therapeutics have? As of today, Keros Therapeutics has 169 employees.
Who is the CEO of Keros Therapeutics? Keros Therapeutics's CEO is Dr. Jasbir Seehra, PhD.
Is Keros Therapeutics publicy listed? Yes, Keros Therapeutics is a public company listed on NAS.
What is the stock symbol of Keros Therapeutics? Keros Therapeutics trades under KROS ticker.
When did Keros Therapeutics go public? Keros Therapeutics went public in 2020.
Who are competitors of Keros Therapeutics? Similar companies to Keros Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Keros Therapeutics? Keros Therapeutics's current market cap is $517M
What is the current revenue of Keros Therapeutics? Keros Therapeutics's last 12-month revenue is $4.1M.
What is the current EBITDA of Keros Therapeutics? Keros Therapeutics's last 12-month EBITDA is -$204M.
What is the current EV/Revenue multiple of Keros Therapeutics? Current revenue multiple of Keros Therapeutics is -6.0x.
What is the current EV/EBITDA multiple of Keros Therapeutics? Current EBITDA multiple of Keros Therapeutics is 0.1x.
What is the current revenue growth of Keros Therapeutics? Keros Therapeutics revenue growth between 2023 and 2024 was 2251%.
Is Keros Therapeutics profitable? Yes, Keros Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.